BlackRock, Inc. ownership in 1CG / CRISPR Therapeutics AG

CRISPR 治療公司

CH ˙ BRSE

Security	CH:1CG / CRISPR Therapeutics AG
Institution	BlackRock, Inc.
Latest Disclosed Ownership	5,932,433 shares
Ownership	6.90%

2025-07-17 - BlackRock, Inc. has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 5,932,433 shares of CRISPR Therapeutics AG (CH:1CG). This represents 6.9 percent ownership of the company.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2025-07-17	2025-07-17	13G		5,932,433		6.90

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-13	2026-03-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	7,680,073	171,895	2.29	365,341	-7.21	0.0064
2026-02-12	2025-12-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	7,508,178	458,033	6.50	393,729	-13.83	0.0067
2025-11-12	2025-09-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	7,050,145	983,787	16.22	456,920	54.85	0.0080
2025-08-12	2025-06-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	6,066,358	3,452,819	132.11	295,068	231.77	0.0056
2025-05-02	2025-03-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,613,539	-145,787	-5.28	88,939	-18.11	0.0019
2025-02-07	2024-12-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,759,326	-35,973	-1.29	108,607	-17.30	0.0022
2024-11-13	2024-09-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,795,299	17,515	0.63	131,323	-12.47	0.0028
2024-08-13	2024-06-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,777,784	231,423	9.09	150,028	-13.56	0.0034
2024-05-10	2024-03-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,546,361	29,875	1.19	173,560	10.17	0.0040
2024-02-13	2023-12-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,516,486	-196,724	-7.25	157,532	27.92	0.0040
2023-11-13	2023-09-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,713,210	-5,365	-0.20	123,153	-19.31	0.0035
2023-08-11	2023-06-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,718,575	-80,006	-2.86	152,621	20.57	0.0042
2023-05-12	2023-03-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,798,581	168,844	6.42	126,580	18.41	0.0037
2023-02-13	2022-12-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,629,737	283,153	12.07	106,899	-30.29	0.0033
2022-11-14	2022-09-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,346,584	194,458	9.04	153,350	17.25	0.0052
2022-08-12	2022-06-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,152,126	-126,648	-5.56	130,785	-8.57	0.0042
2022-05-12	2022-03-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	2,278,774	1,007,246	79.22	143,038	48.44	0.0039
2022-02-10	2021-12-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	1,271,528	142,244	12.60	96,358	-23.77	0.0025
2021-11-09	2021-09-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	1,129,284	78,736	7.49	126,399	-25.68	0.0035
2021-08-11	2021-06-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	1,050,548	-239,787	-18.58	170,075	8.17	0.0047
2021-05-07	2021-03-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	1,290,335	117,076	9.98	157,226	-12.48	0.0046
2021-02-05	2020-12-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	1,173,259	19,416	1.68	179,640	86.14	0.0057
2020-11-06	2020-09-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	1,153,843	141,026	13.92	96,508	29.66	0.0036
2020-08-14	2020-06-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	1,012,817	399,288	65.08	74,434	186.08	0.0030
2020-05-01	2020-03-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	613,529	-15,028	-2.39	26,019	-32.04	0.0013
2020-02-13	2019-12-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	628,557	12,827	2.08	38,283	51.69	0.0015
2019-11-08	2019-09-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	615,730	20,397	3.43	25,238	-10.00	0.0011
2019-08-22	2019-06-30	13F/A-1	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	595,333	-5,148	-0.86	28,041	30.73	0.0012
2019-08-13	2019-06-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	595,333	-5,148		28,041
2019-05-09	2019-03-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	600,481	-38,754	-6.06	21,450	17.44	0.0010
2019-02-08	2018-12-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	639,235	-70,408	-9.92	18,264	-41.97	0.0009
2018-11-09	2018-09-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	709,643	116,116	19.56	31,471	-9.76	0.0014
2018-08-09	2018-06-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	593,527	21,309	3.72	34,876	33.34	0.0016
2018-05-09	2018-03-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	572,218	19,660	3.56	26,156	101.60	0.0013
2018-02-09	2017-12-31	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	552,558	549,254	16,623.91	12,974	21,889.83	0.0006
2017-11-14	2017-09-30	13F	CRISPR THERAPEUTICS	NAMEN AKT	H17182108	3,304	3,304		59		0.0000

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.